Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with Becton Dickinson's life science and diagnostics business, which increased its concentration in diagnostics and discovery-related life science tools.
Last trade$450.32
Day change-$3.105 (-0.68%)
Day range$447.34 – $466.92
Volume275,480
Market cap$89.11B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$89.11B
Price / earnings
907.33×
Price / book
5.83×
Price / sales
15.88×
EV / sales
16.69×
EV / EBITDA
78.89×
Profitability
Earnings per share
$0.50
Return on assets
0.41%
Return on equity
0.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.34×
Current ratio
1.89×
Quick ratio
1.28×
Cash ratio
0.27×
Cash flow
Price / cash flow
185.82×
Price / free cash flow
306.67×
Free cash flow
$290.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for WAT, quarterly periods
Line item
Q3 FY2026 Oct 3, 2026
Q2 FY2026 Jul 4, 2026
Q1 FY2026 Apr 4, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.77B
$1.65B
$1.27B
$932.36M
$800M
$771M
$662M
$872.71M
Cost of revenue
$879M
$911M
$679M
$362.86M
$328M
$321M
$277M
$348.52M
Gross profit
$888M
$734M
$588M
$569.5M
$472M
$450M
$385M
$524.2M
Selling, general and administrative
$398M
$405M
$387M
$240.01M
$214M
$198M
$174M
$173.27M
Research and development
$106M
$122M
$96M
$46.9M
$54M
$49M
$47M
$46.91M
Total operating expenses
$760M
$820M
$635M
$298.98M
$280M
$262M
$233M
$231.94M
Operating income
$128M
-$86M
-$47M
$270.52M
$192M
$188M
$152M
$292.26M
Interest expense
-$59M
-$60M
-$48M
-$14.29M
-$27M
-$15M
-$14M
-$19M
Income before taxes
$75M
-$141M
-$88M
$264.18M
$170M
$178M
$143M
$276.98M
Income taxes
-$7M
-$5M
-$16M
$38.97M
$21M
$31M
$22M
$45.59M
Net income
$82M
-$136M
-$72M
$225.21M
$149M
$147M
$121M
$231.4M
Net income attributable to common shareholders
$81M
-$136M
-$72M
$225.21M
$149M
$147M
$121M
$231.4M
EBITDA
$877M
-$173M
$160M
$323.06M
$301M
$185M
$202M
$340.84M
Basic earnings per share
$0.83
-$1.39
-$0.87
$3.81
$2.50
$2.47
$2.04
$3.90
Diluted earnings per share
$0.82
-$1.39
-$0.87
$3.79
$2.50
$2.47
$2.03
$3.87
Recent news
Company coverage with links to the original publishers.
Waters Corporation received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, ready-to-use flow cytometry tests designed to diagnose B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The tests deliver 96.3% sensitivity and 98.2% specificity, reduce manual steps by 95%, and are expected to launch commercially in spring 2027. The stock rose 2.9% following the announcement.
Waters Corporation announced the acquisition of MOBILion Systems to strengthen its position in the $2 billion LCMS proteomics market. The deal combines MOBILion's SLIM ion mobility separation technology with Waters' mass spectrometry capabilities to enhance protein analysis, biomarker discovery, and AI-driven research workflows. The acquisition is expected to support clinical applications and blood-based diagnostics over time.
Waters Corporation delivered robust third-quarter 2026 results with adjusted EPS rising 21% to $4.10 and revenues surging 121% to $1.77 billion, driven by strong demand for analytical instruments and chemistry consumables. The company raised its 2026 revenue guidance to $6.479B-$6.497B and adjusted EPS guidance to $14.60-$14.70, while announcing the acquisition of MOBILion Systems to strengthen its proteomics market position.
Waters Corporation reported Q3 2026 earnings of $4.1 per share, beating consensus estimates of $3.99, with revenues of $1.77 billion exceeding expectations by 0.81%. The company has consistently beaten estimates over the last four quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Waters shares have gained 18.4% year-to-date versus the S&P 500's 10.2% gain.
Waters Corporation is expected to report Q3 2026 revenues of $1.745-$1.762 billion with adjusted EPS of $3.95-$4.05, representing 16-19% year-over-year growth. The company is anticipated to benefit from strong pharmaceutical spending, increased GLP-1 testing demand, instrument replacement cycles, and contributions from recently acquired Biosciences and Diagnostic Solutions businesses. However, an earnings beat is not predicted by Zacks' model despite positive fundamentals.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.